Oral decitabine plus ivosidenib for older AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of AML with an IDH1 gene mutation.
- You must be 60 or older, or be 18 to 59 with health issues that make intensive chemotherapy too risky.
- You must be able to do daily activities (ECOG performance status 0–2 if 60+, or 0–3 if 18–60).
- Your kidneys and liver must work well enough (creatinine clearance at least 25 mL/min, certain liver enzyme levels within limits).
- You cannot have had prior treatment for AML (except hydroxyurea to lower white blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial combines three drugs—decitabine, venetoclax, and a targeted therapy (olutasidenib)—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It may also be an option for people newly diagnosed with AML who cannot receive intense chemotherapy.
Hear when a new Acute Myeloid Leukemia With Gene Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.